TriangleFOR PATIENTS · SOURCE READING
Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: December 20, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of recurrent hormone-sensitive or hormone-resistant prostate cancer may include:
Source links and citations
Hormone therapy.
Source links and citations
Chemotherapy for patients already treated with hormone therapy.
Source links and citations
Immunotherapy with sipuleucel-T for patients already treated with hormone therapy.
Source links and citations
External radiation therapy.
Source links and citations
Prostatectomy for patients already treated with radiation therapy.
Source links and citations
Alpha emitter radiation therapy.
Source links and citations
PARP inhibitor therapy for patients already treated with hormone therapy who have mutations in certain genes, such as BRCA1 or BRCA2.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice